What should be paid attention to during the use of rhG - CSF injection?
When it comes to the use of rhG - CSF injection, also known as Recombinant Human Granulocyte Colony - Stimulating Factor Injection (Filgrastim), CAS No.: 121181 - 53 - 1 RhG - CSF Injection(Filgrastim) (Recombinant Human Granulocyte Colony - Stimulating Factor) – A Drug To Increase White Blood Cell Count, CAS No.: 121181 - 53 - 1, there are several crucial aspects that users, including medical professionals and patients, should pay close attention to. As a supplier of rhG - CSF injection, I am well - versed in these details and am eager to share them to ensure the safe and effective use of this important medication.
1. Indications and Contraindications
Indications
rhG - CSF injection is primarily used to increase the white blood cell count, especially in patients who have undergone chemotherapy or radiotherapy. Chemotherapy and radiotherapy can often cause myelosuppression, leading to a decrease in white blood cells, which in turn weakens the body's immune system. By stimulating the production and activation of granulocytes in the bone marrow, rhG - CSF injection helps to enhance the immune function and reduce the risk of infection. It is also used in the treatment of severe chronic neutropenia, a condition characterized by an abnormally low level of neutrophils, a type of white blood cell.
Contraindications
However, not everyone can use rhG - CSF injection. Patients with a known hypersensitivity to filgrastim or any of its excipients should avoid its use. Additionally, patients with serious liver, kidney, or heart diseases may require special attention and careful evaluation before using this injection. Pregnant and breastfeeding women should also be cautious, as the effects of rhG - CSF injection on the fetus or infant are not fully understood. Although there is limited evidence suggesting potential risks, it is always advisable to consult a doctor before using the medication.
2. Dosage and Administration
Dosage
The dosage of rhG - CSF injection varies depending on the patient's condition, age, and body weight. For patients undergoing chemotherapy, the usual starting dose is 5 micrograms per kilogram of body weight per day, administered subcutaneously or intravenously. The dosage may be adjusted according to the patient's response, such as the white blood cell count and the severity of neutropenia. In the case of severe chronic neutropenia, the dosage may be higher, starting from 1 microgram per kilogram of body weight per day and adjusted as needed.
Administration
The injection can be given either subcutaneously or intravenously. Subcutaneous injection is usually preferred as it is more convenient and less invasive. When administering subcutaneously, the injection site should be rotated regularly to prevent local irritation. Intravenous administration is typically reserved for patients who cannot tolerate subcutaneous injection or in cases where a rapid increase in white blood cell count is required. It should be administered slowly over a period of time to avoid adverse reactions.
3. Adverse Reactions
Common Adverse Reactions
Like any medication, rhG - CSF injection may cause some adverse reactions. The most common ones include bone pain, which is mainly due to the stimulation of bone marrow activity. This pain is usually mild to moderate and can be relieved with analgesics. Other common adverse reactions include headache, fatigue, nausea, and vomiting. These symptoms are generally transient and will disappear after the treatment is completed or the dosage is adjusted.
Serious Adverse Reactions
Although rare, serious adverse reactions can occur. These include splenic rupture, acute respiratory distress syndrome (ARDS), and allergic reactions. Splenic rupture is a life - threatening complication that may present with abdominal pain and hypotension. ARDS is a severe lung condition characterized by shortness of breath, rapid breathing, and low oxygen levels. Allergic reactions can range from mild skin rashes to severe anaphylaxis, which requires immediate medical attention. Patients should be closely monitored for these serious adverse reactions during the treatment.
4. Drug Interactions
rhG - CSF injection may interact with other medications. For example, it should not be used concurrently with myelosuppressive chemotherapy agents, as this may reduce the effectiveness of rhG - CSF injection. It is also important to inform the doctor about all the medications the patient is taking, including over - the - counter drugs, herbal supplements, and vitamins, to avoid potential drug interactions. Some drugs may enhance or reduce the effects of rhG - CSF injection, which can affect the treatment outcome.
5. Storage and Handling
Storage
rhG - CSF injection should be stored in a refrigerator at 2 - 8°C. It should not be frozen, as freezing can damage the protein structure of the medication and reduce its effectiveness. Once the vial is opened, it should be used immediately or stored in the refrigerator for no more than 24 hours.
Handling
When handling the injection, strict aseptic techniques should be followed to prevent contamination. The injection should be inspected visually for any signs of discoloration, particles, or damage before use. If any abnormalities are found, the injection should not be used.
6. Monitoring and Follow - up
Monitoring
Patients receiving rhG - CSF injection should be closely monitored. Regular blood tests, including complete blood count, should be performed to assess the white blood cell count and the response to the treatment. The doctor will also monitor the patient's vital signs, such as blood pressure, heart rate, and respiratory rate, to detect any potential adverse reactions.
Follow - up
After the treatment is completed, patients should have regular follow - up visits with the doctor. The doctor will evaluate the long - term effects of the treatment and determine if any further treatment is necessary. This is important to ensure the patient's overall health and well - being.
7. Comparison with Other Related Drugs
In the field of oncology and hematology, there are other drugs that also aim to increase the blood cell count. For example, Fosaprepitant Dimeglumine Injection, CAS No.: 265121 - 04 - 8, Bulk and Injection（vial）150mg/5ml is mainly used for preventing chemotherapy - induced nausea and vomiting, while RhIL - 11 Injection(Oprelvekin), CAS No.: 145941 - 26 - 0, (Recombinant Human Interleukin - 11) – A Drug To Increase Platelet Count, RhIL - 11 Injection Lyophilized Powder (vial): 0.75mg/vial, 1.5mg/vial, 3mg/vial is used to increase platelet count. Each of these drugs has its own specific indications and mechanisms of action. rhG - CSF injection, on the other hand, focuses specifically on increasing the white blood cell count, which makes it an essential part of the treatment plan for patients with myelosuppression.
Conclusion
In conclusion, the use of rhG - CSF injection requires careful consideration of various factors, including indications, contraindications, dosage, administration, adverse reactions, drug interactions, storage, and monitoring. By paying close attention to these aspects, medical professionals can ensure the safe and effective use of this medication, and patients can achieve better treatment outcomes. As a supplier of rhG - CSF injection, I am committed to providing high - quality products and relevant information to support the medical community and patients. If you are interested in our rhG - CSF injection products or have any questions regarding its use, please feel free to contact us for procurement and further discussion.
References
- Package insert of rhG - CSF injection
- Clinical guidelines on the use of hematopoietic growth factors
- Medical literature on the safety and efficacy of rhG - CSF injection